Shane Schaffer, Chairman & CEO, and Peter J. Werth, Board Member of Cingulate CING, had been lately company on Benzinga’s All Entry.
Cingulate is a biotechnology firm that’s growing medicine for a variety of underserved situations. The corporate has developed a proprietary expertise referred to as Precision Timed Launch™ (PTR™). The expertise permits a single tablet to include a number of doses of a drug, permitting for aid of the tablet burden many individuals with continual situations endure.
The corporate is making ready an utility for brand spanking new drug approval for its lead candidate, CTx-1301.
Watch the total interview right here:
Featured picture by danilo.alvesd on Unsplash.
This put up incorporates sponsored content material. This content material is for informational functions solely and isn’t meant to be investing recommendation.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
